Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrations
Objective: to study liver transplantation (LT) outcomes in cirrhotic patients with hepatocellular carcinoma(HCC), who underwent transcatheter hepatic arterial chemoembolization (THACE). Materials and methods. From January 1998 to April 2020, we performed 245 orthotopic liver transplantation (OLTs) i...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov
2021-01-01
|
| Series: | Вестник трансплантологии и искусственных органов |
| Subjects: | |
| Online Access: | https://journal.transpl.ru/vtio/article/view/1262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399628792856576 |
|---|---|
| author | D. A. Granov A. S. Polehin P. G. Tarazov I. O. Rutkin I. I. Tileubergenov V. V. Borovik |
| author_facet | D. A. Granov A. S. Polehin P. G. Tarazov I. O. Rutkin I. I. Tileubergenov V. V. Borovik |
| author_sort | D. A. Granov |
| collection | DOAJ |
| description | Objective: to study liver transplantation (LT) outcomes in cirrhotic patients with hepatocellular carcinoma(HCC), who underwent transcatheter hepatic arterial chemoembolization (THACE). Materials and methods. From January 1998 to April 2020, we performed 245 orthotopic liver transplantation (OLTs) in 229 patients of which 25 (10.2%) had HCC in cirrhosis. In 9 (36%) patients, LT was performed without neoadjuvant therapy (Group 1). Group 2 consisted of 16 (66%) patients who underwent 49 THACE cycles before LT. 10 (62.5%) patients fell within the Milan criteria, while 6 (37.5%) were outside. According to the BCLC (Barcelona Clinic Liver Cancer) classification, 10 patients had A1–A4 stage, while 6 were in B stage. In 11 (68.5%) of 16 patients, increased serum alpha-fetoprotein (AFP) concentrations from 20 to 2463 (on average 493.8) ng/mL was revealed before treatment. In performing THACE, both the classical method (with lipiodol and hemostatic sponge) and the method with drug-eluting beads were performed 1 to 7 (on average 3) times. Doxorubicin was used in all cases.Results. Group 2 recorded a 100% technical success. There were no complications. We performed radiofrequency ablation (RFA) in three patients as an adjunct. In two patients, we performed laparoscopic RFA-assisted atypical liver resection, and in one – sequential resection and RFA. Under the m-Recist criteria, complete response was observed in 6 (37.5%), partial response in 7 (43.75%), and stabilization in 3 (18.75%) patients. Change in AFP concentrations were as follows: in 5 out of 11 patients with increased concentrations, we were able to reduce their AFP concentrations to the reference values, their long-term outcomes are comparable to those of Group 1. Four patients showed a 13–84% decrease; a directly proportional relationship between the degree of AFP decrease and the time to tumor progression was revealed. In 2 patients, there were 42% and 320% increase in AFP concentrations, the time to tumor progression was 3 and 1 month, both did not live up to 12 months. Among 9 (56%) of the living 16 patients, a maximum of 156 months and a minimum of 4 months (60.2 average) have elapsed since the surgery. Two of these nine have tumor progression (cases 4 and 14). Seven (44%) patients died within 9 to 54 months. The 1, 3, 5-year actuarial survival rates were 93, 50, 32%, two patients lived more than 10 years. The average life expectancy was 28.0 ± 3.0 months. Conclusion. Serum AFP concentration is an important prognostic factor influencing the long-term outcomes of LT. Good biological response to THACE can be a positive predictor; LT outcomes in these patients are comparable to those in patients who meet the Milan criteria. A decrease in AFP concentrations by less than 50% after neoadjuvant THACE is an unfavorable factor, and its increase is extremely adverse. |
| format | Article |
| id | doaj-art-9758cb08dae441a188ce22f3d4348a4d |
| institution | Kabale University |
| issn | 1995-1191 |
| language | Russian |
| publishDate | 2021-01-01 |
| publisher | Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov |
| record_format | Article |
| series | Вестник трансплантологии и искусственных органов |
| spelling | doaj-art-9758cb08dae441a188ce22f3d4348a4d2025-08-20T03:38:18ZrusFederal Research Center of Transplantology and Artificial Organs named after V.I.ShumakovВестник трансплантологии и искусственных органов1995-11912021-01-01224525710.15825/1995-1191-2020-4-52-57918Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrationsD. A. Granov0A. S. Polehin1P. G. Tarazov2I. O. Rutkin3I. I. Tileubergenov4V. V. Borovik5Granov Russian Scientific Center of Radiology and Surgical TechnologyLeningrad Regional Clinical Oncological DispensaryGranov Russian Scientific Center of Radiology and Surgical TechnologyGranov Russian Scientific Center of Radiology and Surgical TechnologyGranov Russian Scientific Center of Radiology and Surgical TechnologyGranov Russian Scientific Center of Radiology and Surgical TechnologyObjective: to study liver transplantation (LT) outcomes in cirrhotic patients with hepatocellular carcinoma(HCC), who underwent transcatheter hepatic arterial chemoembolization (THACE). Materials and methods. From January 1998 to April 2020, we performed 245 orthotopic liver transplantation (OLTs) in 229 patients of which 25 (10.2%) had HCC in cirrhosis. In 9 (36%) patients, LT was performed without neoadjuvant therapy (Group 1). Group 2 consisted of 16 (66%) patients who underwent 49 THACE cycles before LT. 10 (62.5%) patients fell within the Milan criteria, while 6 (37.5%) were outside. According to the BCLC (Barcelona Clinic Liver Cancer) classification, 10 patients had A1–A4 stage, while 6 were in B stage. In 11 (68.5%) of 16 patients, increased serum alpha-fetoprotein (AFP) concentrations from 20 to 2463 (on average 493.8) ng/mL was revealed before treatment. In performing THACE, both the classical method (with lipiodol and hemostatic sponge) and the method with drug-eluting beads were performed 1 to 7 (on average 3) times. Doxorubicin was used in all cases.Results. Group 2 recorded a 100% technical success. There were no complications. We performed radiofrequency ablation (RFA) in three patients as an adjunct. In two patients, we performed laparoscopic RFA-assisted atypical liver resection, and in one – sequential resection and RFA. Under the m-Recist criteria, complete response was observed in 6 (37.5%), partial response in 7 (43.75%), and stabilization in 3 (18.75%) patients. Change in AFP concentrations were as follows: in 5 out of 11 patients with increased concentrations, we were able to reduce their AFP concentrations to the reference values, their long-term outcomes are comparable to those of Group 1. Four patients showed a 13–84% decrease; a directly proportional relationship between the degree of AFP decrease and the time to tumor progression was revealed. In 2 patients, there were 42% and 320% increase in AFP concentrations, the time to tumor progression was 3 and 1 month, both did not live up to 12 months. Among 9 (56%) of the living 16 patients, a maximum of 156 months and a minimum of 4 months (60.2 average) have elapsed since the surgery. Two of these nine have tumor progression (cases 4 and 14). Seven (44%) patients died within 9 to 54 months. The 1, 3, 5-year actuarial survival rates were 93, 50, 32%, two patients lived more than 10 years. The average life expectancy was 28.0 ± 3.0 months. Conclusion. Serum AFP concentration is an important prognostic factor influencing the long-term outcomes of LT. Good biological response to THACE can be a positive predictor; LT outcomes in these patients are comparable to those in patients who meet the Milan criteria. A decrease in AFP concentrations by less than 50% after neoadjuvant THACE is an unfavorable factor, and its increase is extremely adverse.https://journal.transpl.ru/vtio/article/view/1262hepatocellular carcinomacirrhosishepatic arterial chemoembolizationneoadjuvant therapyliver transplantationalpha-fetoprotein |
| spellingShingle | D. A. Granov A. S. Polehin P. G. Tarazov I. O. Rutkin I. I. Tileubergenov V. V. Borovik Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrations Вестник трансплантологии и искусственных органов hepatocellular carcinoma cirrhosis hepatic arterial chemoembolization neoadjuvant therapy liver transplantation alpha-fetoprotein |
| title | Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrations |
| title_full | Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrations |
| title_fullStr | Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrations |
| title_full_unstemmed | Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrations |
| title_short | Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrations |
| title_sort | transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation the prognostic value of alpha fetoprotein concentrations |
| topic | hepatocellular carcinoma cirrhosis hepatic arterial chemoembolization neoadjuvant therapy liver transplantation alpha-fetoprotein |
| url | https://journal.transpl.ru/vtio/article/view/1262 |
| work_keys_str_mv | AT dagranov transcatheterhepaticarterialchemoembolizationincirrhoticpatientswithhepatocellularcarcinomabeforelivertransplantationtheprognosticvalueofalphafetoproteinconcentrations AT aspolehin transcatheterhepaticarterialchemoembolizationincirrhoticpatientswithhepatocellularcarcinomabeforelivertransplantationtheprognosticvalueofalphafetoproteinconcentrations AT pgtarazov transcatheterhepaticarterialchemoembolizationincirrhoticpatientswithhepatocellularcarcinomabeforelivertransplantationtheprognosticvalueofalphafetoproteinconcentrations AT iorutkin transcatheterhepaticarterialchemoembolizationincirrhoticpatientswithhepatocellularcarcinomabeforelivertransplantationtheprognosticvalueofalphafetoproteinconcentrations AT iitileubergenov transcatheterhepaticarterialchemoembolizationincirrhoticpatientswithhepatocellularcarcinomabeforelivertransplantationtheprognosticvalueofalphafetoproteinconcentrations AT vvborovik transcatheterhepaticarterialchemoembolizationincirrhoticpatientswithhepatocellularcarcinomabeforelivertransplantationtheprognosticvalueofalphafetoproteinconcentrations |